PUMA BIOTECHNOLOGY (PBYI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBYI SEC filings page.
PUMA BIOTECHNOLOGY INC (PBYI) reported $231.2M in revenue over the twelve months to Jun 30, 2026, down 2.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Puma’s sales base is stable, while lower overhead and debt elimination have made the business more profitable and cash-generative.
Across the last two reported years, revenue slipped from$235.6M to$228.4M . Over the same span, operating cash flow rose from$27.0M to$41.8M , showing that cash improvement came from operating efficiency rather than sales expansion.
Latest-year gross margin was
Debt fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of PUMA BIOTECHNOLOGY INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
PUMA BIOTECHNOLOGY INC has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This strong profitability earns a score of 69/100, reflecting efficient cost management and pricing power. This is up from 13.4% the prior year.
PUMA BIOTECHNOLOGY INC's revenue declined 0.9% year-over-year, from $230.5M to $228.4M. This contraction results in a growth score of 26/100.
PUMA BIOTECHNOLOGY INC carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
PUMA BIOTECHNOLOGY INC's current ratio of 2.00 indicates adequate short-term liquidity, earning a score of 58/100. The company can meet its near-term obligations, though with limited headroom.
PUMA BIOTECHNOLOGY INC converts 18.3% of revenue into free cash flow ($41.7M). This strong cash generation earns a score of 80/100.
PUMA BIOTECHNOLOGY INC earns a strong 23.9% return on equity (ROE), meaning it generates $24 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is down from 32.9% the prior year.
PUMA BIOTECHNOLOGY INC scores -2.30, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.3B against total assets of $216.3M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
PUMA BIOTECHNOLOGY INC passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, PUMA BIOTECHNOLOGY INC generates $1.34 in operating cash flow ($41.8M OCF vs $31.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
PUMA BIOTECHNOLOGY INC earns $5.63 in operating income for every $1 of interest expense ($37.3M vs $6.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
PUMA BIOTECHNOLOGY INC generated $56.5M in revenue in Q2 2026. This represents an increase of 7.8% from the same quarter a year earlier. Against the prior quarter it is up 26.1%.
PUMA BIOTECHNOLOGY INC's EBITDA was $10.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
PUMA BIOTECHNOLOGY INC reported $8.2M in net income in Q2 2026. This represents an increase of 39.9% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
PUMA BIOTECHNOLOGY INC earned $0.16 per diluted share (EPS) in Q2 2026. This represents an increase of 33.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
PUMA BIOTECHNOLOGY INC generated $1.6M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 88.5% from the same quarter a year earlier. Against the prior quarter it is down 89.5%.
PUMA BIOTECHNOLOGY INC held $36.5M in cash against $0 in long-term debt as of Q2 2026, with $49.8M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
PUMA BIOTECHNOLOGY INC's gross margin was 77.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
PUMA BIOTECHNOLOGY INC's operating margin was 13.4% in Q2 2026, reflecting core business profitability. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.0 percentage points.
PUMA BIOTECHNOLOGY INC's net profit margin was 14.5% in Q2 2026, showing the share of revenue converted to profit. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.9 percentage points.
PUMA BIOTECHNOLOGY INC's quarterly ROE was 5.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.8 percentage points.
Capital Allocation
PUMA BIOTECHNOLOGY INC invested $18.9M in research and development in Q2 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is down 4.5%.
PUMA BIOTECHNOLOGY INC reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
PBYI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.5M+7.8% | $44.8M-2.6% | $75.5M+27.7% | $54.5M-32.4% | $52.4M+11.4% | $46.0M+5.1% | $59.1M-18.2% | $80.5M+43.5% |
| Cost of Revenue | $12.5M+1.4% | $10.4M-1.3% | $23.1M+66.1% | $12.2M-58.2% | $12.3M+15.4% | $10.6M-1.6% | $13.9M-42.8% | $29.1M+119.0% |
| Gross Profit | $44.0M+9.7% | $34.4M-3.0% | $52.3M+15.9% | $42.3M-17.8% | $40.1M+10.2% | $35.5M+7.3% | $45.2M-5.6% | $51.4M+20.1% |
| R&D Expenses | $18.9M+22.3% | $19.8M+42.8% | $16.8M+11.0% | $15.9M+26.8% | $15.5M+13.4% | $13.9M+2.0% | $15.2M+17.8% | $12.5M+9.6% |
| SG&A Expenses | $17.5M-2.8% | $18.4M+4.7% | $18.4M+10.6% | $16.8M0.0% | $18.0M-27.7% | $17.6M-19.1% | $16.6M-17.6% | $16.8M-26.2% |
| Operating Income | $7.6M+14.3% | -$3.8M-196.1% | $17.1M+28.0% | $9.6M-56.6% | $6.6Mn/m | $4.0Mn/m | $13.4M-9.7% | $22.1M+157.2% |
| EBITDA | $10.1M+10.6% | -$1.2M-118.3% | $20.2M+19.2% | $12.1M-50.9% | $9.1M+2746.1% | $6.8M+1033.8% | $17.0M-7.8% | $24.6M+121.7% |
| Interest Expense | $180K-90.2% | $731K-66.4% | $1.1M-57.3% | $1.5M-52.0% | $1.8M-45.5% | $2.2M-35.2% | $2.6M-21.9% | $3.1M-7.2% |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | -$7.1M-1418.5% | $291K+36.6% |
| Net Income | $8.2M+39.9% | -$3.8M-226.2% | $13.4M-30.4% | $8.8M-56.5% | $5.9Mn/m | $3.0Mn/m | $19.3M+57.4% | $20.3M+250.5% |
| EPS (Basic) | $0.16+33.3% | -$0.07-216.7% | $0.27-30.8% | $0.18-56.1% | $0.12n/m | $0.06n/m | $0.39+50.0% | $0.41+241.7% |
| EPS (Diluted) | $0.16+33.3% | -$0.07-216.7% | $0.26-35.0% | $0.17-58.5% | $0.12n/m | $0.06n/m | $0.40+60.0% | $0.41+241.7% |
| Diluted Shares (Avg) | 53M+4.9% | 51M+1.9% | N/A | 51M+3.6% | 50M+3.8% | 50M+3.6% | N/A | 49M+2.8% |
PBYI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $192.7M-1.1% | $192.7M-1.8% | $216.3M+1.4% | $202.9M-8.1% | $194.9M-4.9% | $196.2M-8.4% | $213.3M-7.5% | $220.7M+8.4% |
| Current Assets | $145.1M+6.2% | $142.3M+7.4% | $162.7M+10.2% | $143.6M-8.4% | $136.6M-0.8% | $132.5M-7.4% | $147.7M-5.5% | $156.8M+25.1% |
| Cash & Equivalents | $36.5M-33.2% | $36.2M-42.6% | $29.6M-57.2% | $53.5M-20.4% | $54.7M-18.6% | $63.0M-17.9% | $69.2M-18.2% | $67.3M-17.8% |
| Short-Term Investments | $57.4M+38.7% | $65.4M+116.8% | $67.9M+113.9% | $40.9M+38.7% | $41.4M+39.3% | $30.1M-0.9% | $31.7M+179.6% | $29.5M+812.4% |
| Inventory | $13.3M+55.1% | $8.7M-0.7% | $5.5M-36.8% | $9.5M+254.5% | $8.6M-5.1% | $8.8M+23.3% | $8.7M+23.2% | $2.7M-52.9% |
| Accounts Receivable | $34.1M+31.5% | $26.3M+4.6% | $53.7M+67.6% | $33.6M-38.6% | $25.9M-7.8% | $25.2M+2.4% | $32.0M-33.1% | $54.6M+88.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $54.2M-39.9% | $64.3M-35.1% | $86.0M-29.1% | $87.6M-41.5% | $90.2M-42.4% | $99.1M-39.3% | $121.2M-31.6% | $149.6M-9.2% |
| Current Liabilities | $49.8M-37.0% | $59.7M-31.1% | $81.3M-15.5% | $82.7M-25.1% | $79.1M-24.2% | $86.7M-11.7% | $96.1M-3.3% | $110.4M+63.9% |
| Non-Current Liabilities | $4.4M-60.7% | $4.5M-63.4% | $4.7M-81.2% | $4.9M-87.6% | $11.1M-78.7% | $12.4M-80.9% | $25.1M-67.7% | $39.2M-59.8% |
| Long-Term Debt | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $10.9M-75.1% | $10.6M-80.5% | $21.7M-66.9% | $32.7M-57.3% |
| Total Equity | $138.5M+32.3% | $128.4M+32.2% | $130.3M+41.5% | $115.3M+62.1% | $104.7M+115.9% | $97.1M+90.5% | $92.1M+72.4% | $71.1M+83.5% |
| Retained Earnings | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m |
Not reported in any period shown, so not listed: Goodwill.
PBYI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.6M-88.5% | $15.4M+326.8% | $14.4M-7.6% | $9.7M-12.2% | $14.1M+1271.2% | $3.6M-67.9% | $15.6M+49.3% | $11.0M+4.0% |
| Depreciation & Amortization | $2.5M+0.6% | $2.6M-7.6% | $2.7M-6.5% | $2.5M0.0% | $2.5M0.0% | $2.8M-3.5% | $2.8M-1.7% | $2.5M0.0% |
| Stock-Based Compensation | $2.0M+20.0% | $1.9M-6.4% | N/A | $1.7M-18.5% | $1.6M-21.0% | $2.0M-14.8% | N/A | $2.1M-19.3% |
| Capital Expenditures | $0-100.0% | $0-100.0% | -$36K+125.0% | $26K+30.0% | $20K0.0% | $61Kn/m | $16K-64.4% | $20K-25.9% |
| Free Cash Flow | $1.6M-88.5% | $15.4M+334.1% | $14.4M-7.7% | $9.7M-12.3% | $14.1M+1296.4% | $3.6M-68.4% | $15.6M+49.8% | $11.0M+4.1% |
| Investing Cash Flow | $8.0Mn/m | $2.5M+61.6% | -$27.0Mn/m | $506K+95.4% | -$11.2M-1700.0% | $1.5Mn/m | -$2.3Mn/m | $259K-97.7% |
| Financing Cash Flow | -$11.3Mn/m | -$11.3Mn/m | -$11.3Mn/m | -$11.3Mn/m | -$11.2Mn/m | -$11.3Mn/m | -$11.3Mn/m | -$11.2Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PBYI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.9%+1.4pp | 76.7%-0.3pp | 69.3%-7.1pp | 77.6%+13.8pp | 76.5%-0.8pp | 77.1%+1.6pp | 76.4%+10.1pp | 63.9%-12.5pp |
| Operating Margin | 13.4%+0.8pp | -8.5%-17.2pp | 22.7%+0.1pp | 17.6%-9.8pp | 12.7%+17.3pp | 8.7%+13.9pp | 22.6%+2.1pp | 27.4%+12.1pp |
| Net Margin | 14.5%+3.3pp | -8.4%-14.8pp | 17.8%-14.9pp | 16.2%-9.0pp | 11.2%+20.8pp | 6.5%+17.5pp | 32.7%+15.7pp | 25.2%+14.9pp |
| Return on Equity | 5.9%+0.3pp | -2.9%-6.0pp | 10.3%-10.7pp | 7.7%-20.9pp | 5.6%+14.9pp | 3.1%+12.5pp | 21.0%-2.0pp | 28.6%+13.6pp |
| Return on Assets | 4.3%+1.3pp | -1.9%-3.5pp | 6.2%-2.8pp | 4.4%-4.8pp | 3.0%+5.2pp | 1.5%+3.8pp | 9.0%+3.7pp | 9.2%+6.3pp |
| Current Ratio | 2.91+1.2x | 2.38+0.9x | 2.00+0.5x | 1.74+0.3x | 1.73+0.4x | 1.53+0.1x | 1.540.0x | 1.42-0.4x |
| Debt-to-Equity | 0.00-0.1x | 0.00-0.1x | 0.00-0.2x | 0.00-0.5x | 0.10-0.8x | 0.11-1.0x | 0.24-1.0x | 0.46-1.5x |
| Liabilities-to-Equity | 0.39-0.5x | 0.50-0.5x | 0.66-0.7x | 0.76-1.3x | 0.86-2.4x | 1.02-2.2x | 1.32-2.0x | 2.10-2.2x |
| Asset Turnover | 0.290.0x | 0.230.0x | 0.35+0.1x | 0.27-0.1x | 0.270.0x | 0.230.0x | 0.280.0x | 0.36+0.1x |
| FCF Margin | 2.9%-23.9pp | 34.4%+26.7pp | 19.1%-7.3pp | 17.7%+4.1pp | 26.8%+24.7pp | 7.7%-18.0pp | 26.4%+12.0pp | 13.7%-5.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PUMA BIOTECHNOLOGY INC PBYI | FY2025 | $228.4M | $31.1M | 13.6% | $563.7M | 68/100 |
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $1.2B | — |
| ProQR Therapeutics N.V. PRQR | FY2025 | $18.7M | -$49.5M | N/A | $175.0M | 72/100 |
| Tonix Pharmaceuticals Holding Corp. TNXP | FY2025 | $13.1M | -$124.0M | N/A | $90.9M | 70/100 |
Where PUMA BIOTECHNOLOGY INC Ranks
Frequently Asked Questions
What is PUMA BIOTECHNOLOGY INC's annual revenue?
PUMA BIOTECHNOLOGY INC (PBYI) reported $228.4M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is PUMA BIOTECHNOLOGY INC's revenue growing?
PUMA BIOTECHNOLOGY INC (PBYI) revenue declined by 0.9% year-over-year, from $230.5M to $228.4M in fiscal year 2025.
Is PUMA BIOTECHNOLOGY INC profitable?
Yes, PUMA BIOTECHNOLOGY INC (PBYI) reported a net income of $26.7M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $31.1M, with a net profit margin of 13.6%.
What is PUMA BIOTECHNOLOGY INC's EBITDA?
PUMA BIOTECHNOLOGY INC (PBYI) had EBITDA of $48.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does PUMA BIOTECHNOLOGY INC have?
As of fiscal year 2025, PUMA BIOTECHNOLOGY INC (PBYI) had $29.6M in cash and equivalents against $0 in long-term debt.
What is PUMA BIOTECHNOLOGY INC's gross margin?
PUMA BIOTECHNOLOGY INC (PBYI) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is PUMA BIOTECHNOLOGY INC's operating margin?
PUMA BIOTECHNOLOGY INC (PBYI) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is PUMA BIOTECHNOLOGY INC's net profit margin?
PUMA BIOTECHNOLOGY INC (PBYI) had a net profit margin of 13.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is PUMA BIOTECHNOLOGY INC's return on equity (ROE)?
PUMA BIOTECHNOLOGY INC (PBYI) has a return on equity of 23.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is PUMA BIOTECHNOLOGY INC's free cash flow?
PUMA BIOTECHNOLOGY INC (PBYI) generated $41.7M in free cash flow during fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is PUMA BIOTECHNOLOGY INC's operating cash flow?
PUMA BIOTECHNOLOGY INC (PBYI) generated $41.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are PUMA BIOTECHNOLOGY INC's total assets?
PUMA BIOTECHNOLOGY INC (PBYI) had $216.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are PUMA BIOTECHNOLOGY INC's capital expenditures?
PUMA BIOTECHNOLOGY INC (PBYI) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does PUMA BIOTECHNOLOGY INC spend on research and development?
PUMA BIOTECHNOLOGY INC (PBYI) invested $62.1M in research and development during fiscal year 2025.
What is PUMA BIOTECHNOLOGY INC's current ratio?
PUMA BIOTECHNOLOGY INC (PBYI) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.
What is PUMA BIOTECHNOLOGY INC's debt-to-equity ratio?
PUMA BIOTECHNOLOGY INC (PBYI) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is PUMA BIOTECHNOLOGY INC's liabilities-to-equity ratio?
PUMA BIOTECHNOLOGY INC (PBYI) had a liabilities-to-equity ratio of 0.66 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is PUMA BIOTECHNOLOGY INC's return on assets (ROA)?
PUMA BIOTECHNOLOGY INC (PBYI) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is PUMA BIOTECHNOLOGY INC's P/E ratio?
PUMA BIOTECHNOLOGY INC (PBYI) trades at 21.1x earnings, its market capitalization divided by $26.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $563.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PUMA BIOTECHNOLOGY INC's price-to-sales ratio?
PUMA BIOTECHNOLOGY INC (PBYI) trades at 2.4x sales, its market capitalization divided by $231.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $563.7M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PUMA BIOTECHNOLOGY INC's Altman Z-Score?
PUMA BIOTECHNOLOGY INC (PBYI) has an Altman Z-Score of -2.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is PUMA BIOTECHNOLOGY INC's Piotroski F-Score?
PUMA BIOTECHNOLOGY INC (PBYI) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PUMA BIOTECHNOLOGY INC's earnings high quality?
PUMA BIOTECHNOLOGY INC (PBYI) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can PUMA BIOTECHNOLOGY INC cover its interest payments?
PUMA BIOTECHNOLOGY INC (PBYI) has an interest coverage ratio of 5.63x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is PUMA BIOTECHNOLOGY INC?
PUMA BIOTECHNOLOGY INC (PBYI) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.